CorMedix Reports Q4 Revenue Surge Amid Mixed Earnings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CRMD?
Source: stocktwits
- Significant Revenue Growth: CorMedix reported Q4 revenue of $128.6 million, a remarkable 312% year-on-year increase, driven by $91.2 million from DefenCath sales and $37.4 million from the Melinta portfolio, indicating initial success from the acquisition integration.
- Sharp Rise in Expenses: Total operating expenses surged to $48.2 million in Q4, up 181% year-on-year, primarily due to $4.1 million in one-time costs related to the Melinta acquisition, reflecting financial pressures during the expansion and integration phases.
- Strong Cash Position: CorMedix ended 2025 with $148.5 million in cash and short-term investments, maintaining robust liquidity despite high expenditures, which provides a solid foundation for future growth initiatives.
- Market Reaction Volatility: Despite exceeding revenue expectations, CorMedix's stock fell over 11% post-earnings release due to concerns over EPS falling short of estimates, yet retail sentiment on social media shifted to bullish, indicating investor optimism about future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRMD
Wall Street analysts forecast CRMD stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.120
Low
13.00
Averages
13.67
High
15.00
Current: 7.120
Low
13.00
Averages
13.67
High
15.00
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CorMedix Scheduled to Announce Q4 Earnings on March 5th
- Earnings Announcement Schedule: CorMedix (CRMD) is set to announce its Q4 2023 earnings on March 5th before market open, with consensus EPS estimates at $0.81 and revenue at $127.02 million, highlighting investor interest in the company's financial performance.
- Historical Performance Review: Over the past two years, CRMD has only beaten EPS estimates 25% of the time and revenue estimates 38% of the time, indicating uncertainty in the company's financial forecasting, which may affect investor confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen one upward and one downward revision, while revenue estimates have experienced two upward and five downward revisions, reflecting divergent market views on the company's future performance, potentially leading to stock price volatility.
- Stock Buyback Plan: CorMedix has announced a $75 million stock buyback plan aimed at enhancing shareholder value, although the recent disappointing revenue outlook for 2026 may negatively impact the stock price.
See More
CorMedix Q4 2025 Earnings Misses Expectations
- Disappointing Earnings Report: CorMedix reported Q4 2025 earnings per share of $0.16, missing market expectations by $0.66, resulting in a ~12% drop in stock price to the lowest level in nearly 11 months, indicating significant challenges in profitability.
- Tax Expense Impact: The company recorded $42.4 million in tax expenses for Q4, leading to a ~20% year-over-year decline, which negatively affected overall financial performance and highlighted the burden of tax liabilities on earnings.
- Significant Revenue Growth: Despite challenges, CorMedix's operating income surged over 350% year-over-year to $59.1 million, with total revenue witnessing a more than fourfold increase to $128.6 million, exceeding market expectations by $1.6 million, showcasing strong product demand.
- Stable Future Outlook: The company reaffirmed its revenue guidance for 2026, projecting between $300 million and $320 million, compared to analysts' forecast of $308.96 million, reflecting management's confidence in future growth.
See More
CorMedix Reports Q4 Revenue Surge Amid Mixed Earnings
- Significant Revenue Growth: CorMedix reported Q4 revenue of $128.6 million, a remarkable 312% year-on-year increase, driven by $91.2 million from DefenCath sales and $37.4 million from the Melinta portfolio, indicating initial success from the acquisition integration.
- Sharp Rise in Expenses: Total operating expenses surged to $48.2 million in Q4, up 181% year-on-year, primarily due to $4.1 million in one-time costs related to the Melinta acquisition, reflecting financial pressures during the expansion and integration phases.
- Strong Cash Position: CorMedix ended 2025 with $148.5 million in cash and short-term investments, maintaining robust liquidity despite high expenditures, which provides a solid foundation for future growth initiatives.
- Market Reaction Volatility: Despite exceeding revenue expectations, CorMedix's stock fell over 11% post-earnings release due to concerns over EPS falling short of estimates, yet retail sentiment on social media shifted to bullish, indicating investor optimism about future performance.
See More
CorMedix Q4 Earnings Beat Expectations, Share Buyback Plan Approved
- Earnings Performance: CorMedix reported a Q4 GAAP EPS of $0.16, missing expectations by $0.66, yet revenue reached $128.62 million, reflecting a 312.1% year-over-year increase and beating estimates by $1.6 million, indicating strong momentum in revenue growth.
- Adjusted EBITDA: The company reported an adjusted EBITDA of $77.2 million, showcasing improvements in operational efficiency and cost control; while GAAP EPS fell short, the overall financial health remains robust.
- Cash Reserves: As of December 31, 2025, CorMedix's cash and short-term investments, excluding restricted cash, totaled $148.5 million, providing ample financial support for future investments and operations.
- Share Buyback Plan: CorMedix's Board of Directors approved a share repurchase program of up to $75 million, aimed at enhancing shareholder value and demonstrating confidence in the company's stock, which is expected to have a positive impact on share price.
See More
CorMedix Reports Significant Q4 Profit Growth
- Profit Performance: CorMedix reported a fourth-quarter profit of $14.02 million, translating to earnings per share of $0.16, which, while lower than last year's $0.20, indicates stability in profitability.
- Revenue Surge: The company's revenue for the fourth quarter soared to $128.62 million, a staggering 312.1% increase from $31.21 million last year, reflecting strong product demand and successful market expansion.
- Year-over-Year Comparison: Although earnings per share declined, the substantial revenue growth compared to the previous year suggests enhanced competitiveness in the market, potentially attracting more investor interest.
- Future Outlook: With rapid revenue growth, CorMedix is positioned to continue expanding its market share and enhancing its standing in the biopharmaceutical industry, further driving long-term growth.
See More
CorMedix Reports Strong Q4 and Full-Year 2025 Financial Results
- Q4 Revenue Surge: CorMedix reported net revenue of $128.6 million for Q4 2025, primarily driven by continued utilization of DefenCath among outpatient dialysis customers, with sales reaching $91.2 million, indicating strong market demand and product acceptance.
- Significant Annual Performance: Total revenue for 2025 was $311.7 million, a substantial increase from 2024, and with the acquisition of Melinta, pro forma total revenue is projected to reach $401.3 million, reflecting the company's success in expanding its product portfolio.
- Improved Profitability: The company achieved a net income of $14.0 million in Q4, with adjusted EBITDA of $77.2 million, demonstrating effective cost control and operational efficiency despite a 182% year-over-year increase in operating expenses.
- Positive Future Outlook: CorMedix reiterated its guidance for 2026, expecting net revenue between $300 million and $320 million and adjusted EBITDA between $100 million and $125 million, showcasing confidence in future growth, particularly with upcoming REZZAYO clinical data releases.
See More
CorMedix Scheduled to Announce Q4 Earnings on March 5th
- Earnings Announcement Schedule: CorMedix (CRMD) is set to announce its Q4 2023 earnings on March 5th before market open, with consensus EPS estimates at $0.81 and revenue at $127.02 million, highlighting investor interest in the company's financial performance.
- Historical Performance Review: Over the past two years, CRMD has only beaten EPS estimates 25% of the time and revenue estimates 38% of the time, indicating uncertainty in the company's financial forecasting, which may affect investor confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen one upward and one downward revision, while revenue estimates have experienced two upward and five downward revisions, reflecting divergent market views on the company's future performance, potentially leading to stock price volatility.
- Stock Buyback Plan: CorMedix has announced a $75 million stock buyback plan aimed at enhancing shareholder value, although the recent disappointing revenue outlook for 2026 may negatively impact the stock price.
See More
CorMedix Q4 2025 Earnings Misses Expectations
- Disappointing Earnings Report: CorMedix reported Q4 2025 earnings per share of $0.16, missing market expectations by $0.66, resulting in a ~12% drop in stock price to the lowest level in nearly 11 months, indicating significant challenges in profitability.
- Tax Expense Impact: The company recorded $42.4 million in tax expenses for Q4, leading to a ~20% year-over-year decline, which negatively affected overall financial performance and highlighted the burden of tax liabilities on earnings.
- Significant Revenue Growth: Despite challenges, CorMedix's operating income surged over 350% year-over-year to $59.1 million, with total revenue witnessing a more than fourfold increase to $128.6 million, exceeding market expectations by $1.6 million, showcasing strong product demand.
- Stable Future Outlook: The company reaffirmed its revenue guidance for 2026, projecting between $300 million and $320 million, compared to analysts' forecast of $308.96 million, reflecting management's confidence in future growth.
See More
CorMedix Reports Q4 Revenue Surge Amid Mixed Earnings
- Significant Revenue Growth: CorMedix reported Q4 revenue of $128.6 million, a remarkable 312% year-on-year increase, driven by $91.2 million from DefenCath sales and $37.4 million from the Melinta portfolio, indicating initial success from the acquisition integration.
- Sharp Rise in Expenses: Total operating expenses surged to $48.2 million in Q4, up 181% year-on-year, primarily due to $4.1 million in one-time costs related to the Melinta acquisition, reflecting financial pressures during the expansion and integration phases.
- Strong Cash Position: CorMedix ended 2025 with $148.5 million in cash and short-term investments, maintaining robust liquidity despite high expenditures, which provides a solid foundation for future growth initiatives.
- Market Reaction Volatility: Despite exceeding revenue expectations, CorMedix's stock fell over 11% post-earnings release due to concerns over EPS falling short of estimates, yet retail sentiment on social media shifted to bullish, indicating investor optimism about future performance.
See More
CorMedix Q4 Earnings Beat Expectations, Share Buyback Plan Approved
- Earnings Performance: CorMedix reported a Q4 GAAP EPS of $0.16, missing expectations by $0.66, yet revenue reached $128.62 million, reflecting a 312.1% year-over-year increase and beating estimates by $1.6 million, indicating strong momentum in revenue growth.
- Adjusted EBITDA: The company reported an adjusted EBITDA of $77.2 million, showcasing improvements in operational efficiency and cost control; while GAAP EPS fell short, the overall financial health remains robust.
- Cash Reserves: As of December 31, 2025, CorMedix's cash and short-term investments, excluding restricted cash, totaled $148.5 million, providing ample financial support for future investments and operations.
- Share Buyback Plan: CorMedix's Board of Directors approved a share repurchase program of up to $75 million, aimed at enhancing shareholder value and demonstrating confidence in the company's stock, which is expected to have a positive impact on share price.
See More
CorMedix Reports Significant Q4 Profit Growth
- Profit Performance: CorMedix reported a fourth-quarter profit of $14.02 million, translating to earnings per share of $0.16, which, while lower than last year's $0.20, indicates stability in profitability.
- Revenue Surge: The company's revenue for the fourth quarter soared to $128.62 million, a staggering 312.1% increase from $31.21 million last year, reflecting strong product demand and successful market expansion.
- Year-over-Year Comparison: Although earnings per share declined, the substantial revenue growth compared to the previous year suggests enhanced competitiveness in the market, potentially attracting more investor interest.
- Future Outlook: With rapid revenue growth, CorMedix is positioned to continue expanding its market share and enhancing its standing in the biopharmaceutical industry, further driving long-term growth.
See More
CorMedix Reports Strong Q4 and Full-Year 2025 Financial Results
- Q4 Revenue Surge: CorMedix reported net revenue of $128.6 million for Q4 2025, primarily driven by continued utilization of DefenCath among outpatient dialysis customers, with sales reaching $91.2 million, indicating strong market demand and product acceptance.
- Significant Annual Performance: Total revenue for 2025 was $311.7 million, a substantial increase from 2024, and with the acquisition of Melinta, pro forma total revenue is projected to reach $401.3 million, reflecting the company's success in expanding its product portfolio.
- Improved Profitability: The company achieved a net income of $14.0 million in Q4, with adjusted EBITDA of $77.2 million, demonstrating effective cost control and operational efficiency despite a 182% year-over-year increase in operating expenses.
- Positive Future Outlook: CorMedix reiterated its guidance for 2026, expecting net revenue between $300 million and $320 million and adjusted EBITDA between $100 million and $125 million, showcasing confidence in future growth, particularly with upcoming REZZAYO clinical data releases.
See More
